Join Relievus

If you're a physician, and you're looking for a better way to deliver care, consider joining our team.

Find out more

Call to schedule your appointment today

888-985-2727 (ASAP)


Don’t let Rheumatoid arthritis diminish your quality of life!

Many of us take actions like walking up steps or turning a doorknob for granted. But these everyday movements can be excruciating if you live with rheumatoid arthritis (RA).

Rheumatoid arthritis affects joint linings, causing painful swelling. Over long periods, the inflammation associated with rheumatoid arthritis can cause bone erosion and joint deformity.

📍Pain areas: in the joints, back, or muscles
📍Joints: stiffness, swelling, tenderness, or weakness
📍Whole body: fatigue, anemia, or malaise
📍Skin: lumps or redness
📍Hand: bump on the finger or swelling
📍Also common: flare, dry mouth, physical deformity, or sensation of pins and needles

Let Relievus help you ease the pain.
Call us to book your appointment:


By |October 19th, 2022|Categories: News||0 Comments

Clearway Pain Solutions Merges with Relievus Pain Management

Creates One of the Largest Multi-State Integrated Pain Solutions Organizations in the Country and Expands Footprint in Mid-Atlantic

ANNAPOLIS, Md., July 14, 2022 /PRNewswire/ — Clearway Pain Solutions (“Clearway” or “the company”) today announced it has merged with Relievus Pain Management (“Relievus”), creating one of the largest integrated pain solutions practices in the United States.  The combined organization includes 143 practitioners practicing in 67 locations throughout six states and significantly expands the company’s footprint into Pennsylvania and New Jersey. 

Relievus Logo
Relievus Logo

Relievus is based in Cherry Hill, NJ and was founded in 2008 by Dr. Young Lee. The practice is now comprised of 16 physicians, 19 advanced practitioners, five acupuncturists, three behavioral health professionals, and one physical therapist, treating patients in 19 locations in New Jersey and Pennsylvania.

“I am excited to join these two extraordinary teams and continue providing excellent pain management care to the Mid-Atlantic Region,” said Clearway Pain Solutions CEO, Dr. Damean Freas. “We are now able to offer greatly needed pain management services to more patients, attract and retain industry leading talent, and provide the most advanced treatments that make a real difference in our patients’ lives.”

“Over the last few years, we have conducted a comprehensive search for a partner with complementary goals that could help our practice expand and position us to continue to provide superior pain management services to the communities that we serve,” said Dr. Lee. “Clearway is the right partner for us, and we are excited to become a part of the Clearway team and build upon the success Relievus has established over the past 14 years. Together, we believe Clearway and Relievus will become the preeminent pain management practice in the United States.”

Clearway and Relievus will continue the work in their respective communities to act as trusted practice to send patients in need of specialized pain management. Both companies have a long history of effectively partnering with community physicians, Worker’s Compensation carriers, and law firms to provide quality interventional pain management care for those they serve, and the companies will continue to deliver the state-of-the-art treatment options for patients suffering from chronic pain.

Clearway Pain Solutions will remain the flagship brand, with corporate headquarters in Annapolis, MD. The combined organization will leverage financial, operational, clinical, and technological resources as part of a national strategy to deliver excellence in comprehensive interventional pain management services. 

Details of the transaction were not disclosed.

Contact: Britni Cullen

SOURCE Clearway Pain Solutions

By |July 19th, 2022|Categories: News||Comments Off on Clearway Pain Solutions Merges with Relievus Pain Management

Common Chronic Pain

Common forms of chronic pain include: Back pain, neck pain, head injuries, and neurological conditions. Relievus has pain management specialists skilled in treating these forms of pain with state of the art treatments.

You can learn more about these common sources of pain by clicking the link below:

By |June 22nd, 2022|Categories: News||0 Comments

Herniated Discs Causing You Pain?

The discs in your back function as rubbery cushions between the bones, which make up the spine. These discs act as natural shock absorbers. When a disc becomes damaged, it can cause compression of the spinal nerves. This is what we call a disc herniation.

Relievus has state of the art pain doctors here to treat the underlying causes of disc herniation to help relieve your chronic pain!
Learn more here:

By |May 9th, 2022|Categories: News||Comments Off on Herniated Discs Causing You Pain?

Have Backpain? We Can Help!

Having back pain is difficult, as even minimal pain can be unbearable at times. It may interfere with your ability to work and function in daily living. At Relievus, we are here to help you alleviate pain as well as make it easier to tolerate.

By |April 11th, 2022|Categories: News||Comments Off on Have Backpain? We Can Help!

Cervical Radiculopathy Treatment

Cervical Radiculopathy refers to damage or irritation of nerve roots that exit the cervical spine. This condition is an irritation or compression of one or more nerve roots in the cervical spine.

Depending on where the pressure is on a cervical nerve, symptoms may include:
Weakness, numbness, or tingling in the arms and hands
Pain along the back of the arms
Hand, neck, and shoulder pain
Neck mobility impairment

Please visit the rest of our website to learn more:

By |March 9th, 2022|Categories: News||Comments Off on Cervical Radiculopathy Treatment

How We Can Help Treat CRPS

Complex regional pain syndrome (CRPS) is a broad term describing excess and prolonged pain and inflammation that follows an injury to an arm or leg. CRPS has acute (recent, short-term) and chronic (lasting greater than six months) forms.

People with CRPS have changing combinations of spontaneous pain or excess pain that is much greater than normal following something as mild as a touch. Other symptoms include changes in skin color, temperature, and/or swelling on the arm or leg below the site of injury.

Learn about how Relievus treats CRPS with innovative medicine:

By |February 14th, 2022|Categories: News||Comments Off on How We Can Help Treat CRPS

You Are On The Right Path With Relievus

Part of what makes chronic pain such a challenge is that it not only hurts physically, but also emotionally. If you’ve landed on this post searching for the good pain doctors, you are on the right path. We can help you.

Please know that we design personalized treatment to make you feel better. Real solutions to your chronic pain. Please visit our website to see the conditions we specialize in treating:

By |January 17th, 2022|Categories: News||Comments Off on You Are On The Right Path With Relievus

What 83 studies say about ketamine and mental health

  • University of Exeter researchers have published a review of research evaluating ketamine’s value in mental health therapy.
  • The review of studies found that ketamine may quickly alleviate depression and thoughts of suicide.
  • Ketamine’s usefulness for other mental health conditions is less clear.
  • Ketamine use is not without hazards.

Doctors primarily use ketamine as a general anesthetic for medical procedures during which a person must be unconscious, but muscle relaxation is not required. Ketamine is also a dissociative medication, and researchers have been exploring the use of sub-anesthetic dosages of ketamine for treating depression for some time.

Researchers at the University of Exeter in the United Kingdom have reported that an analysis of existing studies confirms that ketamine therapy offers fast-acting, short-term relief from depression and, to some extent, suicidal thoughts and other mental health symptoms.

The meta-analysis of 83 existing studies has assessed the value of ketamine therapy for treating a wide range of mental health conditions. These studies include 29 randomized controlled trials, 21 observational studies, and 33 systematic reviews/.  The study features in the British Journal of Psychiatry Open. The team carried it out in collaboration with the University of British Columbia and with support from the Society for the Study of Addiction.

The strongest effect that the studies document is the value of intravenous ketamine therapy for relieving depression.

A reduction in unipolar depression severity occurred within anywhere from 1 to 24 hours, and it lasted for 1–2 weeks. In comparison, oral doses took up to 2 weeks to have an effect.

Bipolar depression relief was also rapid, occurring as quickly as 4 hours after administration and consistently by 24 hours. The full effect lasted for up to 3 days, with some relief still apparent after 7 days.

The studies also support the use of ketamine for treating affective disorders and thoughts of suicide.

Of suicidal ideation, co-author and University of Exeter Ph.D. candidate Ozden Merve Mollaahmetoglu told GMHCN. 

“It is really interesting that there is some evidence of an effect on suicidal thoughts independent of depressive symptoms, and it would be great to understand the mechanism of this effect. This finding is important because there is a risk of suicide in several mental health problems, so it would be interesting to see if we could treat suicidal thoughts in other conditions, such as substance use disorders.”

Mollaahmetoglu also noted: “Since the effect of ketamine on suicidal thoughts was short-lived, it would also be important to determine how this can be extended — for instance, in combination with psychotherapy. We also don’t know whether multiple doses of ketamine are more effective than a single dose for reducing suicidal thoughts, as this hasn’t been directly compared.”

Other research found some therapeutic benefit to the use of ketamine for other psychiatric disorders such as “post-traumatic stress disorder, obsessive-compulsive disorder, anxiety, and substance use disorders.” However, write the authors, “the evidence base comprised a small number of mostly nonrandomized trials with often short follow-up periods, therefore requiring corroboration and extension.”Safe in a clinical setting

The study emphasizes the importance of restricting the administration of ketamine to carefully controlled clinical circumstances.

Mollaahmetoglu told GMHCN:

“Ketamine is a very safe drug in a clinical setting. When people are given ketamine, we see mild increases in blood pressure and heart rate, which can be monitored and managed in clinical settings.” She also noted that people who might be at “increased risk of negative psychological reactions to ketamine, like people with a personal or family history of schizophrenia, can be screened out.”

Additionally, in such a setting, “People are provided with preparation and psychological support during and after the ketamine infusions, which likely reduces [the] risk of adverse psychological reactions.”

Finally, it is possible to protect individuals in a clinical setting from accidental injury and physical vulnerability due to ketamine’s dissociative effect. This effect promotes a “reduced awareness of their environment, lack of coordination, inability to communicate, and considerably diminished sensory input.”Ketamine requires caution

Dr. Alan F. Schatzberg, a professor of psychiatry and behavioral sciences at Stanford University, told MNT that “whether, in fact, these drugs are effective enough to be worth it is still unanswered.”

Dr. Schatzberg cautioned, “I haven’t seen enough real data to say that we [have] got a huge winner there.”

His concern is that, “ketamine works through an opioid mechanism, and ketamine in certain forms and in certain situations, it’s highly addictive.”

Dr. Schatzberg also noted the difficulty of conducting unbiased, blind studies of ketamine’s effect on mental health due to the disassociation it produces because “a patient, in fact, has a sense of what drug or placebo they got.” He recalled that in some approved esketamine trials, “they didn’t ask the patients, ‘Hey, do you think you got [the] drug or placebo?’”

“The way the study frames it,” said Dr. Schatzberg, “is positive, positive, positive. But you know, you have to wonder when you’re dealing with something like ketamine.”

By |January 12th, 2022|Categories: News||0 Comments

Ketamine therapy swiftly reduces depression and suicidal thoughts

Ketamine therapy has a swift short-term effect on reducing symptoms of depression and suicidal thoughts, according to a review of all the available evidence. systematic review led by the University of Exeter and funded by the Medical Research Council analyzed evidence from 83 published research papers. The strongest evidence emerged around the use of ketamine to treat both major depression and bipolar depression. Symptoms were reduced as swiftly as one to four hours after a single treatment, and lasted up to two weeks. Some evidence suggested that repeated treatment may prolong the effects, however more high-quality research is needed to determine by how long

Similarly, single or multiple doses of ketamine resulted in moderate to large reductions in suicidal thoughts. This improvement was seen as early as four hours following ketamine treatment and lasted on average three days, and up to a week.

Lead author Merve Mollaahmetoglu, of the University of Exeter, said: “Our research is the most comprehensive review of the growing body of evidence on the therapeutic effects of ketamine to date. Our findings suggest that ketamine may be useful in providing rapid relief from depression and suicidal thoughts, creating a window of opportunity for further therapeutic interventions to be effective. It’s important to note that this review examined ketamine administration in carefully controlled clinical settings where any risks of ketamine can be safely managed.

For other psychiatric disorders, including anxiety disorders, post-traumatic stress disorders and obsessive-compulsive disorders, there is early evidence to suggest the potential benefit of ketamine treatment. Moreover, for individuals with substance use disorders, ketamine treatment led to short-term reductions in craving, consumption and withdrawal symptoms.Published in the British Journal of Psychiatry Open, the review synthesizes the evidence from a growing field of research into the potential benefits of ketamine for conditions for which there are limited effective treatments. The review included 33 systematic reviews, 29 randomized control trials, and 21 observational studies.

Ketamine’s effects on depressive symptoms and suicidal thoughts are supported by numerous systematic reviews and meta-analyses, which provide an exhaustive overview of research in a given topic. These are considered to have the highest strength of evidence compared to other types of studies, increasing confidence in the evidence for ketamine’s antidepressant and anti-suicidal effects.

However, ketamine’s therapeutic effects for psychiatric conditions other than depression and suicidal thoughts are based on small number of studies that did not randomize people into different treatment arms. These effects require replication in larger randomized placebo-controlled trials, which are considered as gold standard.

The authors noted a number of difficulties in the research field, which they recommend that future studies should seek to address. One factor is the bias created because participants realize they have been given ketamine, rather than a saline solution. Senior author Professor Celia Morgan, of the University of Exeter, said: “We’re finding that ketamine may have promising benefits for conditions that are notoriously hard to treat in clinic. We now need bigger and better-designed trials to test these benefits. For example, due to ketamine’s unique subjective effects participants may be able to tell whether they have been given ketamine or a saline solution as the placebo, potentially creating an expectation about the effects of the drug. This effect may be better controlled by having active placebo-controlled trials, where the control group receives another drug with psychoactive properties.”

A number of questions remain unanswered in the research field, including the optimal dose, route of administration and number of doses of ketamine treatment. There is also a need for further research on the added and interactive benefit of psychotherapy alongside ketamine treatment.

Additionally, the importance of ketamine’s acute subjective effects in its therapeutic benefits has not been fully explored. More research is also needed on how to optimize participants’ preparation for ketamine treatment and the setting in which ketamine treatment is delivered.

The research involved collaboration with the University of British Columbia, and received support from the Society for the Study of Addiction. The paper is entitled “Ketamine for the treatment of mental health and substance use disorders: a comprehensive systematic review,” and is published in the British Journal of Psychiatry Open.


By |January 3rd, 2022|Categories: News||0 Comments